482740
nNOS - PSD-95 Interaction Inhibitor, ZL006
The nNOS - PSD-95 Interaction Inhibitor, ZL006 controls the biological activity of nNOS. This small molecule/inhibitor is primarily used for Cancer applications.
Synonym(s):
nNOS - PSD-95 Interaction Inhibitor, ZL006, 5-(3,5-dichloro-2-hydroxybenzylamino)-2-hydroxybenzoic acid
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Recommended Products
Quality Level
Assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
color
off-white
solubility
DMSO: 50 mg/mL
shipped in
ambient
storage temp.
−20°C
General description
A cell-permeable and blood-brain barrier-permeant aminosalicylic acid compound that selectively disrupts nNOS and PSD-95 interaction upon NMDAR activation both in primary murine cortical neuron cultures (0.8- and 2.8-fold increase from basal level with or without 30 min 10 uM ZL006 pretreatment before 30 min Glu-Gly stimulation) in vitro and in mice subjected to middle brain artery occlusion (0.4- and 1.9-fold increase from basal level with or without inhibitor pretreatment 15 min before MACO; 1.5 mg/kg i.v.) in vivo without affecting nNOS activity or non-nNOS-mediated NMDAR EPSCs (excitatory postsynaptic currents) in rat hippocampus. Its therapeutic efficacy in limiting ischemia-caused brain tissue damage has been demonstrated in both mice and rats when applied 1 h after blood reperfusion following MACO (60% and 50% reduction of infarction, respectively; 1.5 mg/kg i.v.).
A cell-permeable and blood-brain barrier-permeant aminosalicylic acid compound that selectively disrupts nNOS and PSD-95 interaction upon NMDAR activation both in primary murine cortical neurons (0.8- and 2.8-fold increase from basal level with or without 30 min 10 uM ZL006 pretreatment) in vitro and in mice (0.4- and 1.9-fold increase from basal level with or without inhibitor pretreatment 15 min before ischemia; 1.5 mg/kg i.v.) in vivo without affecting nNOS activity or non-nNOS-mediated NMDAR EPSCs (excitatory postsynaptic currents). Effectively reduce ischemia-caused brain tissue damage in both mice and rats when applied 1 h after blood reperfusion following ishemia (60% and 50% reduction of infarction, respectively; 1.5 mg/kg i.v.).
Packaging
Packaged under inert gas
Warning
Toxicity: Regulatory Review (Z)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Zhou, L., et al. 2010. Nature Med.16, 1439.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service